Previous studies have reported that IL-6 or IL-6 downstream signaling confers chemotherapeutic resistance by triggering the PI3K/Akt, MAPK/ERK, or Jak1/STAT3 signaling pathway in cancer cells [36–38]. The gene discussed is AKT1; the disease is cancer.